xoma
highlights
recent
royalty
asset
portfolio
developments
reports
third
quarter
financial
results
company
recently
earned
million
milestone
payment
advanced
phase
development
advanced
pancreatic
cancer
undisclosed
partner
entered
phase
development
triggering
million
milestone
rezolute
financing
resulted
accelerated
million
payment
two
partners
presented
early
stage
data
scientific
conferences
acquired
royalty
interest
four
lysosomal
storage
disorder
enzymes
developed
chiesi
group
additional
assets
advanced
next
stages
clinical
development
even
though
clinical
trial
enrollment
across
industry
remains
challenging
due
pandemic
emeryville
globe
newswire
xoma
corporation
nasdaq
xoma
today
announced
recent
royalty
asset
portfolio
advancements
third
quarter
financial
results
partners
continue
make
advances
missions
bring
new
therapies
patients
need
recently
two
separate
partners
dosed
first
patients
respective
phase
studies
novartis
monoclonal
antibody
patients
metastatic
pancreatic
cancer
one
undisclosed
partner
phase
trial
undisclosed
indication
two
events
resulted
earning
combined
million
milestones
portion
million
novartis
milestone
applied
reduce
novartis
debt
obligation
less
million
stated
jim
neal
chief
executive
officer
xoma
another
three
partners
announced
initiation
phase
studies
third
quarter
bayer
osocimab
convert
study
patients
kidney
failure
requiring
hemodialysis
rezolute
study
congenital
hyperinsulinism
incyte
triple
combination
therapy
study
select
advanced
malignancies
additionally
medical
community
received
first
look
early
data
two
assets
portfolio
merck
alligator
janssen
mitazalimab
mab
via
presentations
medical
conferences
summer
pleased
learn
rezolute
completed
sizable
fundraise
attracted
investors
successful
financing
resulted
accelerated
payment
million
xoma
neal
continued
royalty
interest
acquisition
front
exercised
option
acquire
royalty
rights
associated
enzymes
investigated
potential
treatments
four
lysosomal
storage
disorders
bioasis
strategic
alliance
chiesi
group
basket
enzymes
expands
portfolio
beyond
monoclonal
antibodies
small
molecules
adds
another
four
assets
potential
milestone
royalty
portfolio
disclosed
undisclosed
financial
results
xoma
recorded
total
revenues
million
third
quarter
compared
million
third
quarter
decrease
three
months
ended
september
compared
corresponding
period
primarily
due
million
recognized
rezolute
agreement
million
recognized
janssen
license
agreement
third
quarter
research
development
expenses
million
third
quarter
compared
million
third
quarter
decrease
million
three
months
ended
september
compared
period
due
million
decrease
salary
related
expenses
result
recategorization
employees
department
codes
mapped
general
administrative
expenses
general
administrative
g
expenses
million
third
quarter
compared
million
third
quarter
decrease
million
corresponding
periods
primarily
due
million
decrease
salary
related
expenses
million
decrease
facilities
costs
third
quarter
g
expenses
included
million
compensation
expense
company
net
cash
used
operations
million
third
quarter
xoma
recorded
million
total
interest
expense
compared
million
corresponding
period
reflect
company
outstanding
loan
balances
silicon
valley
bank
svb
novartis
net
loss
third
quarter
million
compared
net
income
million
third
quarter
september
xoma
cash
million
company
ended
december
cash
million
since
september
xoma
earned
million
including
debt
reduction
partners
company
continues
believe
current
cash
balance
sufficient
fund
xoma
operations
multiple
years
xoma
corporation
xoma
built
significant
portfolio
products
licensed
developed
biotechnology
pharmaceutical
companies
company
portfolio
programs
spans
multiple
stages
drug
development
process
across
various
therapeutic
areas
many
licenses
result
xoma
pioneering
efforts
discovery
development
antibody
therapeutics
company
business
model
includes
acquiring
additional
licenses
programs
funding
information
visit
statements
explanatory
notes
certain
statements
contained
press
release
statements
within
meaning
section
securities
act
section
securities
exchange
act
including
statements
regarding
potential
xoma
portfolio
partnered
programs
licensed
technologies
generating
substantial
milestone
royalty
proceeds
time
creating
additional
value
stockholders
cash
sufficiency
forecast
economic
outlook
potential
impact
pandemic
statements
based
assumptions
may
prove
accurate
actual
results
could
differ
materially
anticipated
due
certain
risks
inherent
biotechnology
industry
including
related
fact
product
candidates
subject
agreements
still
developed
licensees
may
require
substantial
funds
continue
development
may
available
know
whether
continue
viable
market
products
ownership
royalty
interest
therapeutic
product
candidates
royalty
interest
receive
regulatory
approval
licensees
able
market
impact
global
economy
result
pandemic
potential
risks
xoma
meeting
expectations
described
detail
xoma
recent
filing
form
sec
filings
consider
risks
carefully
considering
xoma
prospects
statement
press
release
represents
xoma
views
date
press
release
relied
upon
representing
views
subsequent
date
xoma
disclaims
obligation
update
looking
statement
except
required
applicable
law
explanatory
note
references
portfolio
press
release
refer
strictly
milestone
royalty
rights
associated
basket
drug
products
development
references
assets
press
release
refer
strictly
milestone
royalty
rights
associated
individual
drug
products
development
references
royalties
royalty
rates
strictly
refer
future
potential
payment
streams
regardless
whether
technically
defined
royalties
underlying
contractual
agreement
rates
referenced
herein
subject
potential
future
contractual
adjustments
date
press
release
assets
xoma
milestone
royalty
portfolio
investigational
compounds
efficacy
safety
established
guarantee
assets
become
commercially
available
xoma
corporation
condensed
consolidated
balance
sheets
unaudited
thousands
except
share
per
share
amounts
september
december
assets
current
assets
cash
trade
receivables
net
income
tax
receivable
prepaid
expenses
current
assets
total
current
assets
property
equipment
net
operating
lease
assets
royalty
receivables
equity
securities
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
liabilities
contingent
consideration
royalty
purchase
agreements
operating
lease
liabilities
unearned
revenue
recognized
method
contract
liabilities
current
portion
debt
total
current
liabilities
unearned
revenue
recognized
method
debt
operating
lease
liabilities
liabilities
total
liabilities
stockholders
equity
convertible
preferred
stock
par
value
shares
authorized
shares
issued
outstanding
september
december
respectively
common
stock
par
value
shares
authorized
shares
issued
outstanding
september
december
respectively
additional
capital
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
xoma
corporation
condensed
consolidated
statements
operations
comprehensive
income
loss
unaudited
thousands
except
per
share
amounts
three
months
ended
september
nine
months
ended
september
revenues
revenue
contracts
customers
revenue
recognized
method
total
revenues
operating
expenses
research
development
general
administrative
total
operating
expenses
loss
income
operations
income
expense
net
interest
expense
income
net
loss
income
income
tax
income
tax
benefit
net
loss
income
comprehensive
loss
income
net
loss
income
comprehensive
loss
income
available
common
stockholders
basic
net
loss
income
comprehensive
loss
income
available
common
stockholders
diluted
basic
net
loss
income
per
share
available
common
stockholders
diluted
net
loss
income
per
share
available
common
stockholders
weighted
average
shares
used
computing
basic
net
loss
income
per
share
available
common
stockholders
weighted
average
shares
used
computing
diluted
net
loss
income
per
share
available
common
stockholders
investor
contact
juliane
snowden
oratorium
group
llc
jsnowden
media
contact
kathy
vincent
kv
consulting
management
kathy
